Abstract
Acute renal failure (ARF) represents a severe complication of malignancies, that causes significant morbidity and mortality. ARF is a common part of multiple organ dysfunction in critically ill patients with cancer with reported mortality rates from 72% to 85% in patients who need renal replacement therapy. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, certain factors leading to the development of ARF may be associated to the tumor or to the tumor therapy. The purpose of this review is to give specific aspects of renal disease in critically ill cancer patients (CICPs), to overview the causes of ARF in CICPs and to describe recent progress in the management of these complications, including treatment toxicity and bone marrow transplantation (BMT). The prevention of ARF is obligatory and therefore the possible treatments of ARF in CICPs are also discussed.
Keywords: Acute renal failure, tumor lysis syndrome, hepatocellular carcinoma (HCC), multiple myeloma, lymphoma.
Current Medicinal Chemistry
Title:Acute Renal Failure in Different Malignant Tumors
Volume: 23 Issue: 19
Author(s): Sanja Radojevic-Skodric, Ljiljana Bogdanovic, Milena Jovanovic, Ivana Baralic, Zoran Dzamic, Ron Gordon, Simona Ognjanovic and Gordana Basta-Jovanovic
Affiliation:
Keywords: Acute renal failure, tumor lysis syndrome, hepatocellular carcinoma (HCC), multiple myeloma, lymphoma.
Abstract: Acute renal failure (ARF) represents a severe complication of malignancies, that causes significant morbidity and mortality. ARF is a common part of multiple organ dysfunction in critically ill patients with cancer with reported mortality rates from 72% to 85% in patients who need renal replacement therapy. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, certain factors leading to the development of ARF may be associated to the tumor or to the tumor therapy. The purpose of this review is to give specific aspects of renal disease in critically ill cancer patients (CICPs), to overview the causes of ARF in CICPs and to describe recent progress in the management of these complications, including treatment toxicity and bone marrow transplantation (BMT). The prevention of ARF is obligatory and therefore the possible treatments of ARF in CICPs are also discussed.
Export Options
About this article
Cite this article as:
Radojevic-Skodric Sanja, Bogdanovic Ljiljana, Jovanovic Milena, Baralic Ivana, Dzamic Zoran, Gordon Ron, Ognjanovic Simona and Basta-Jovanovic Gordana, Acute Renal Failure in Different Malignant Tumors, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/0929867323666160407113245
DOI https://dx.doi.org/10.2174/0929867323666160407113245 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on the Extraneuronal Monoamine Transporter (EMT): Characteristics, Distribution and Regulation
Current Drug Metabolism Antitumor Activity of Benzamide Riboside In Vitro and In Vivo
Current Medicinal Chemistry Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Microarray RNA/DNA in Different Stem Cell Lines
Current Pharmaceutical Biotechnology The Role of Cytochrome P450 in Herb-Drug Interactions
Current Pharmacogenomics Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Current Molecular Medicine Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Designing Promiscuous Drugs? Look at What Nature Made!
Letters in Drug Design & Discovery Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma
Protein & Peptide Letters Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry